Sign In
Buy XBI
$129.83
+2.07 (+1.62%)
At Close: Jun 03, 2026
Biotech ETFs Slip After Novavax Cuts 2022 Guidance
08:39am, Thursday, 11'th Aug 2022
Biotechnology sector-related exchange traded funds retreated with Novavax Inc. (NasdaqGS: NVAX), plunging after the vaccine developer cut its 2022 revenue guidance in half. On Tuesday, the iShares Gen
Biotech ETFs Rally as Global Blood Therapeutics Surges on Potential Pfizer Deal
09:42pm, Friday, 05'th Aug 2022
Biotechnology sector-related exchange traded funds continued to rally Friday on reports that Pfizer Inc. (NYSE: PFE) is looking to acquire Global Blood Therapeutics (NasdaqGS: GBT). On Friday, the Vir
Biotech ETFs Advance on Speculation of a Takeover Bid for Global Blood Therapeutics
06:51pm, Thursday, 04'th Aug 2022
Global Blood Therapeutics (NasdaqGS: GBT) shares climbed Thursday, lifting biotechnology sector-related exchange traded funds, on speculation of takeover bids for the small drug developer. On Thursday
The 3 Best Market Sectors for the Second Half of 2022
09:36am, Wednesday, 27'th Jul 2022
Inflation fears delivered the worst first-half performance for the stock market since 1970. Fortunately, the second half is unlikely to echo the destruction because equities have already baked in a mi
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
07:47am, Friday, 22'nd Jul 2022
Smart Beta ETF report for XBI
Is It Time to Buy the Dip With Biotech Stocks?
10:23am, Thursday, 21'st Jul 2022
Right now, it's even riskier to buy biotechs than normal.
XBI: Are Biotech Stocks A Good Investment Again?
02:07pm, Wednesday, 20'th Jul 2022
Biotech stocks, as reflected by the XBI ETF, are down ~40% since Jan 1, 2021, underperforming the broader markets. The drug price control political climate in Washington since January 2021 likely has
Has the Market Bottomed? 6 ETFs in High Momentum
10:08am, Wednesday, 20'th Jul 2022
These ETFs are in high momentum as some traders believe that markets have reached a bottom.
ETF Filings Heat Up In July
06:29pm, Tuesday, 19'th Jul 2022
A range of compelling new offerings from stalwarts and newcomers are shaking up the industry.
Final Trades: XBI, UNH, KWEB & DHR
07:17pm, Friday, 15'th Jul 2022
The final trades of the week. With CNBC's Joe Kernen and the Fast Money traders, Tim Seymour, Jeff Mills, Bonawyn Eison and Steve Grasso.
XBI's Strong Relative Outperformance Is Likely To Continue
07:44am, Thursday, 14'th Jul 2022
XBI is an equal weighted fund of biotechnology companies. XBI bottomed in May through June, and has outperformed the broader market since then.
Final Trades: CVS, Disney, Biotech & more
02:00pm, Wednesday, 13'th Jul 2022
The "Halftime Report" traders give their top picks to watch for the second half.
Biotech Public Offerings at 10-Year Low
04:56pm, Monday, 11'th Jul 2022
No matter how you slice it, this has been a poor year for biotechnology stocks. Not only is the SPDR S&P Biotech ETF ( XBI , Financial) down nearly 29% year to date, but biotech initial public offerin
5 ETFs Riding High on the Biotech Comeback
12:25pm, Friday, 08'th Jul 2022
Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.
Health-care stocks could do well during economic contraction, says Renaissance's Jeff Degraaf
05:43pm, Wednesday, 06'th Jul 2022
Jeff Degraaf, Renaissance Macro Research chairman, joins 'Closing Bell: Overtime' to discuss biotech and other sectors to watch.
